John Overdeck’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-59,844
| Closed | -$2.38M | – | 5106 |
|
|
2026
Q1 | $2.38M | Buy |
59,844
+2,400
| +4% | +$61.4K | ﹤0.01% | 2620 |
|
|
2025
Q4 | $1.44M | Hold |
57,444
| – | – | ﹤0.01% | 2695 |
|
|
2025
Q3 | $1.39M | Sell |
57,444
-14,700
| -20% | -$261K | ﹤0.01% | 2364 |
|
|
2025
Q2 | $948K | Buy |
72,144
+56,844
| +372% | +$720K | ﹤0.01% | 2287 |
|
|
2025
Q1 | $220K | Sell |
15,300
-22,600
| -60% | -$370K | ﹤0.01% | 2825 |
|
|
2024
Q4 | $635K | Sell |
37,900
-66,008
| -64% | -$1.09M | ﹤0.01% | 2420 |
|
|
2024
Q3 | $1.66M | Buy |
103,908
+52,108
| +101% | +$638K | ﹤0.01% | 1787 |
|
|
2024
Q2 | $468K | Sell |
51,800
-26,981
| -34% | -$256K | ﹤0.01% | 2403 |
|
|
2024
Q1 | $890K | Buy |
78,781
+62,281
| +377% | +$590K | ﹤0.01% | 2024 |
|
|
2023
Q4 | $131K | Buy |
16,500
+4,900
| +42% | +$32.9K | ﹤0.01% | 2915 |
|
|
2023
Q3 | $75.1K | Buy |
11,600
+500
| +5% | +$3.42K | ﹤0.01% | 2773 |
|
|
2023
Q2 | $68.7K | Buy |
+11,100
| New | +$52.7K | ﹤0.01% | 2794 |
|
|
2021
Q3 | – | Sell |
-9,973
| Closed | -$222K | – | 4296 |
|
|
2021
Q2 | $222K | Buy |
+9,973
| New | +$234K | ﹤0.01% | 3722 |
|
John Overdeck's CNTA Position: Q2 2026 in Review
John Overdeck sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 59,844 shares — an estimated $2.38M sold.
John Overdeck first reported a position in CNTA in Q2 2021 and held it in 13 quarters. The position peaked at $2.38M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- John Overdeck reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- John Overdeck sold 59,844 Centessa Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
- John Overdeck first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 13 quarters.
- John Overdeck's Centessa Pharmaceuticals position peaked at $2.38M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.